REVIEW Thyroid Hormone Receptors Regulate Adipogenesis And

Total Page:16

File Type:pdf, Size:1020Kb

REVIEW Thyroid Hormone Receptors Regulate Adipogenesis And 143 REVIEW Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors Changxue Lu and Sheue-Yann Cheng Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 5128, Bethesda, Maryland 20892-4264, USA (Correspondence should be addressed to S-Y Cheng; Email: [email protected]) Abstract Peroxisome proliferator-activated receptors (PPARs) and thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily. They are ligand-dependent transcription factors that interact with their cognate hormone response elements in the promoters to regulate respective target gene expression to modulate cellular functions. While the transcription activity of each is regulated by their respective ligands, recent studies indicate that via multiple mechanisms PPARs and TRs crosstalk to affect diverse biological functions. Here, we review recent advances in the understanding of the molecular mechanisms and biological impact of crosstalk between these two important nuclear receptors, focusing on their roles in adipogenesis and carcinogenesis. Journal of Molecular Endocrinology (2010) 44, 143–154 Introduction (NR1C3; Fig. 1), are encoded by three different genes (PPARA, PPARD, and PPARG) located at chromosomes Peroxisome proliferator-activated receptors (PPARs) 22, 6, and 3 respectively. Upon ligand binding, PPARs and thyroid hormone receptors (TRs) are ligand- are recruited to peroxisome proliferator response dependent transcription receptors of the subfamily 1 elements (PPREs) in the regulatory region of target (NR1) in the nuclear receptor superfamily. The NR1 genes as heterodimers with the auxiliary factor RXR. group also includes retinoic acid receptors (RARs), With the PPAR/RXR heterodimers, either partner can Rev-erb, RAR-related orphan receptors (RORs), bind cognate ligands and elicit ligand-dependent oxysterol receptors (LXRs), vitamin D3 receptors transactivation (Kliewer et al. 1992). The canonical (VDRs), and the nuclear xenobiotic receptor (constitu- PPRE contains two direct repeats of the hormone tive androstane receptor, CAR). PPARs and TRs share a response element (HRE) half site (AGGTCA) with a conserved DNA-binding domain (DBD) and exert their 1 bp spacer in between (DR1; Kliewer et al. 1992, activity partly by heterodimerization with a common Tugwood et al. 1992). partner, the retinoid X receptor (RXR), to regulate the Natural and synthetic ligands have been reported for transcription of target genes. PPARs and TRs each have the three PPAR isotypes (Balakumar et al. 2007, diverse effects on developmental and metabolic pro- Bensinger & Tontonoz 2008; Table 1 and Fig. 2). For cesses as well as in diseases such as obesity, diabetes, and PPARa, ligands include natural unsaturated fatty acids cancer. The first part of this review describes current (FAs), leukotriene, hydroxyeicosatetraenoic acids understanding of PPAR and TR biology. The second (HETEs), and synthetic hypolipemia-inducing drugs part highlights recent advances in the understanding of such as fibrates. The PPARd ligands are less well known, molecular mechanisms underlying the PPAR–TR cross- but FAs have been suggested to be natural ligands for talks, with particular emphasis on the role of such this subtype of PPAR (Fyffe et al. 2006). Recent studies crosstalk in metabolism and carcinogenesis. identified a few more PPARd agonists, namely tetra- decylthioacetic acid (TTA), L-165041, and GW501516 Peroxisome proliferator-activated receptors (Berger et al. 1999, Oliver et al. 2001, Westergaard et al. 2001). For PPARg, endogenous ligands include PPARs, which consist of PPARa (NR1C1), PPARb/d polyunsaturated FAs, prostanoids, and oxidized FAs (NR1C2, hereafter referred to as PPARd), and PPARg found in low-density lipoproteins (Forman et al. 1995, Journal of Molecular Endocrinology (2010) 44, 143–154 DOI: 10.1677/JME-09-0107 0952–5041/10/044–143 q 2010 Society for Endocrinology Printed in Great Britain Online version via http://www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/29/2021 11:23:24AM via free access 144 CLUand S-Y CHENG . Crosstalk of TR with PPAR signalling DBD LBD glucose metabolism and insulin sensitization. That A Domains: A/B CD E/F PPARg also has a dominant role in adipogenesis is B PPAR isoforms: 1 100 174 468 α suggested by many loss-of-function studies both in vivo 1 73 146 441 and in vitro (Fajas et al. 2001). β/δ 86% 70% 1 109 183 477 γ1 83% 68% 1 29 137 211 505 Thyroid hormone receptors γ2 83% 68% α In humans, TRs are encoded by two genes, THRA and C TR isoforms: 1 51 128 410 α1 THRB, located at chromosomes 17 and 3 respectively. 1 154 The THRA gene encodes three TRa (NR1A1) isoforms, ∆α1 1 51 128 370 409 492 TRa1, TRa2, and TRa3, which differ in their carboxyl α2 terminus as a result of alternative splicing of the 1 115 154 237 ∆α2 primary transcripts (Fig. 1). TRa1 binds triiodothy- 1 51 128 370 453 α3 ronine (T3) and activates or represses target genes, whereas TRa2andTRa3donotbindT3,and β D TR isoforms: 1 94 107 174 181 461 β1 may antagonize T3 action (Izumo & Mahdavi 1988, 1 147 160 227 234 514 Mitsuhashi et al. 1988, Macchia et al. 2001). The THRA β2 gene also yields two truncated proteins known as 1 23 36 103 110 390 β3 TRDa1 and TRDa2, which play a role in intestinal 1 8 288 ∆β3 development (Chassande et al. 1997, Plateroti et al. 2001). The THRB gene encodes two amino-terminal Figure 1 Schematic representation of the structures of PPARs TRb (NR1A2) protein variants – TRb1 and TRb2. In and TRs. (A) Modular domain structures of nuclear receptors in general. Two most conserved domains, DBD (C domain) and LBD rodents, the same gene also gives rise to TRb3 and a (E/F domain), are colored in gray and black respectively. (B) The truncated protein TRDb3, which lacks the DBD human PPAR homologs. Compared with the DBD of PPARa (Williams 2000, Harvey et al. 2007). (NR1C1), sequence homology is 86 and 83% in PPARb/d TRs bind to thyroid hormone response elements (NR1C2) and PPARg1/2 (NR1C3) respectively. In LBD, sequences are less conserved with only 70 and 68% of homology (TREs) in target genes as homodimers as well as for PPARb/d and PPARg1/2 respectively using the sequence of heterodimers with RXR. Most naturally occurring PPARa as a reference. (C and D) Structural comparison of rat positive TREs identified to date include two repeats of TRa isoforms (C) and rat TRb isoforms (D). The areas of identical the half site 50-AGGTCA-30, which is also shared by shading indicate conserved sequences among the isoforms. The PPREs arranged as a direct repeat with 4 bps between three major TRa isoforms (TRa1, a2, and a3) mainly differ in LBD at the carboxyl terminus; TRb isoforms (TRb1, b2, and b3) mainly the two half sites (DR4). Among known TREs, inverted differ in amino-terminal A/B domain. repeats (also called palindromes; e.g. GGTCAT- GACCTA) and everted repeats (e.g. GACCT(N6)- AGGTCA, N: any nucleotide) have also been reported Kliewer et al. 1995, Davies et al. 2001). Synthetic ligands (Glass et al. 1988, Brent et al. 1989, Farsetti et al. 1992, g for PPAR include anti-diabetic drugs, such as rosigli- Forman et al. 1992). TRs have also been shown to tazone and pioglitazone of the thiazolidinedione class. heterodimerize with other nuclear receptors, such as This wide variety of ligands for PPARs requires a flexible PPARs and VDRs (Bogazzi et al. 1994, Schrader et al. plasticity in the PPAR ligand-binding domain, which is 1994). In the presence of PPARa,TRb has binding suggested by the PPARg crystallized structure (Nolte affinity to a DR2 present in the myelin proteolipid et al. 1998). protein gene promoter but not to the classical TRE, PPARa is predominantly expressed in tissues with DR4, located in the malic enzyme gene. Upon thyroid high turnover rates of FA metabolism, such as liver, hormone stimulation, the DR2-driven reporter gene is brown adipose tissue (BAT), heart, and kidney. The activated by the TRb–PPARa heterodimer but not by target genes of PPARa are mainly involved in mito- TRa–PPARa,TRa–RXRb,orTRb–RXRb. Three amino chondrial and peroxisomal b-oxidation of FAs and acids in the D box of the DBD in TRb are critical for this apolipoprotein synthesis. PPARd is ubiquitously heterodimerization. The dissimilarity of the D boxes expressed in tissues. Its target genes are involved in between TRb and TRa may be responsible for this FA oxidation, fuel switch, mitochondrial respiration, isoform-dependent protein interaction and the DNA- and thermogenesis (Barish et al. 2006, Furnsinn et al. binding sequence specificity (Bogazzi et al.1994). 2007). PPARg expression is mainly found in BAT and In humans, the DBDs of TRs and PPARs are highly white adipose tissue (WAT) and, to a lesser extent, in homologous. Importantly, TRs and PPARs share the the large intestine, retina, and some immune cells (e.g. same proximal box (P-box) sequence in DBD, which is macrophage and T lymphocyte; Ricote et al. 1998, critical in sequence-specific recognition of HRE by Harris & Phipps 2001). Activation of PPARg affects NRs, while providing contact surface with the major Journal of Molecular Endocrinology (2010) 44, 143–154 www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/29/2021 11:23:24AM via free access Crosstalk of TR with PPAR signalling . CLUand S-Y CHENG 145 Table 1 Ligands for peroxisome proliferator-activated receptors (PPARs) and thyroid hormone receptors (TRs) Endogenous ligands Synthetic ligands Receptors PPARa Polyunsaturated FAs, leukotriene B4 (LTB4), Clofibrate, fenofibrate, bezafibrate, gemfibrozil, HETE (Kliewer et al. 1997) ciprofibrate, Wy14 643 (Willson et al. 2000), BMS-687453, BMS-711939 (Mukherjee et al. 2008) PPARb/d Unsaturated or saturated long-chain Fas, prostacyclin, TTA, L-165,041, GW501516 eicosanoids, HODE (oxidized FA; Shureiqi et al.
Recommended publications
  • Dualism of Peroxisome Proliferator-Activated Receptor Α/Γ: a Potent Clincher in Insulin Resistance
    AEGAEUM JOURNAL ISSN NO: 0776-3808 Dualism of Peroxisome Proliferator-Activated Receptor α/γ: A Potent Clincher in Insulin Resistance Mr. Ravikumar R. Thakar1 and Dr. Nilesh J. Patel1* 1Faculty of Pharmacy, Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Gujarat, India. [email protected] Abstract: Diabetes mellitus is clinical syndrome which is signalised by augmenting level of sugar in blood stream, which produced through lacking of insulin level and defective insulin activity or both. As per worldwide epidemiology data suggested that the numbers of people with T2DM living in developing countries is increasing with 80% of people with T2DM. Peroxisome proliferator-activated receptors are a family of ligand-activated transcription factors; modulate the expression of many genes. PPARs have three isoforms namely PPARα, PPARβ/δ and PPARγ that play a central role in regulating glucose, lipid and cholesterol metabolism where imbalance can lead to obesity, T2DM and CV ailments. It have pathogenic role in diabetes. PPARα is regulates the metabolism of lipids, carbohydrates, and amino acids, activated by ligands such as polyunsaturated fatty acids, and drugs used as Lipid lowering agents. PPAR β/δ could envision as a therapeutic option for the correction of diabetes and a variety of inflammatory conditions. PPARγ is well categorized, an element of the PPARs, also pharmacological effective as an insulin resistance lowering agents, are used as a remedy for insulin resistance integrated with type- 2 diabetes mellitus. There are mechanistic role of PPARα, PPARβ/δ and PPARγ in diabetes mellitus and insulin resistance. From mechanistic way, it revealed that dual PPAR-α/γ agonist play important role in regulating both lipids as well as glycemic levels with essential safety issues.
    [Show full text]
  • CDR Clinical Review Report for Soliqua
    CADTH COMMON DRUG REVIEW Clinical Review Report Insulin glargine and lixisenatide injection (Soliqua) (Sanofi-Aventis) Indication: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) alone or in combination with metformin. Service Line: CADTH Common Drug Review Version: Final (with redactions) Publication Date: January 2019 Report Length: 118 Pages Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • Synthesis of a Coumarin-Based PPAR Fluorescence Probe for Competitive Binding Assay
    International Journal of Molecular Sciences Article Synthesis of a Coumarin-Based PPARγ Fluorescence Probe for Competitive Binding Assay Chisato Yoshikawa, Hiroaki Ishida , Nami Ohashi and Toshimasa Itoh * Laboratory of Drug Design and Medicinal Chemistry, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan; [email protected] (C.Y.); [email protected] (H.I.); [email protected] (N.O.) * Correspondence: [email protected] Abstract: Peroxisome proliferator-activated receptor γ (PPARγ) is a molecular target of metabolic syndrome and inflammatory disease. PPARγ is an important nuclear receptor and numerous PPARγ ligands were developed to date; thus, efficient assay methods are important. Here, we investigated the incorporation of 7-diethylamino coumarin into the PPARγ agonist rosiglitazone and used the com- pound in a binding assay for PPARγ. PPARγ-ligand-incorporated 7-methoxycoumarin, 1, showed weak fluorescence intensity in a previous report. We synthesized PPARγ-ligand-incorporating coumarin, 2, in this report, and it enhanced the fluorescence intensity. The PPARγ ligand 2 main- tained the rosiglitazone activity. The obtained partial agonist 6 appeared to act through a novel mechanism. The fluorescence intensity of 2 and 6 increased by binding to the ligand binding domain (LBD) of PPARγ and the affinity of reported PPARγ ligands were evaluated using the probe. Keywords: PPARγ ligand; coumarin; fluorescent ligand; screening; crystal structure Citation: Yoshikawa, C.; Ishida, H.; Ohashi, N.; Itoh, T. Synthesis of a Coumarin-Based PPARγ 1. Introduction Fluorescence Probe for Competitive Binding Assay. Int. J. Mol. Sci. 2021, Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor su- 22, 4034.
    [Show full text]
  • Comparison of Clinical Outcomes and Adverse Events Associated with Glucose-Lowering Drugs in Patients with Type 2 Diabetes: a Meta-Analysis
    Online Supplementary Content Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA. doi:10.1001/jama.2016.9400. eMethods. Summary of Statistical Analysis eTable 1. Search Strategies eTable 2. Description of Included Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 3. Description of Included Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 4. Description of Included Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin Plus Sulfonylurea eTable 5. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Monotherapy eTable 6. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Dual Therapy Added to Metformin eTable 7. Risks of Bias in Clinical Trials Evaluating Drug Classes Given as Triple Therapy When Added to Metformin plus Sulfonylurea eTable 8. Estimated Global Inconsistency in Networks of Outcomes eTable 9. Estimated Heterogeneity in Networks eTable 10. Definitions of Treatment Failure Outcome eTable 11. Contributions of Direct Evidence to the Networks of Treatments eTable 12. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes Given as Monotherapy eTable 13. Network Meta-analysis Estimates of Comparative Treatment Associations for Drug Classes When Used in Dual Therapy (in Addition to Metformin) eTable 14. Network Meta-analysis Estimates of Comparative Treatment Effects for Drug Classes Given as Triple Therapy eTable 15. Meta-regression Analyses for Drug Classes Given as Monotherapy (Compared With Metformin) eTable 16. Subgroup Analyses of Individual Sulfonylurea Drugs (as Monotherapy) on Hypoglycemia eTable 17.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Comparative Safety and Effectiveness of Type 2 Diabetes Medicines Final Report September 2014
    Type 2 Diabetes review – ToR 4 COMPARATIVE SAFETY AND EFFECTIVENESS OF TYPE 2 DIABETES MEDICINES FINAL REPORT SEPTEMBER 2014 A report by the Centre for Applied Health Economics (CAHE), Griffith University Type 2 Diabetes review – ToR 4 This report was commissioned by the Pharmaceutical Evaluation Branch, Department of Health, the Australian Government. Researchers: Erika Turkstra Senior research fellow, health technology assessment Martin Downes Research fellow, health technology assessment Emilie Bettington Senior research assistant Tracy Comans Senior research fellow, health technology assessment Paul Scuffham Professor and chair in health economics The assistance of Sanjeewa Kularatna with the data extraction and Gabor Mihala with the statistical analyses is appreciated. The advice provided by the Post-Market Review Section, Pharmaceutical Evaluation Branch, Department of Health and the Reference Group is also appreciated. Type 2 Diabetes review – ToR 4 CONTENTS ACRONYMS ............................................................................................................. III EXECUTIVE SUMMARY ............................................................................................ 1 PURPOSE OF THE REVIEW ........................................................................................... 1 BACKGROUND ............................................................................................................ 1 REVIEW OF CLINICAL GUIDELINES ...............................................................................
    [Show full text]
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
    [Show full text]
  • Regulation of Enac-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors
    Hindawi Publishing Corporation PPAR Research Volume 2010, Article ID 703735, 9 pages doi:10.1155/2010/703735 Review Article Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors Tengis S. Pavlov,1 John D. Imig,2, 3 and Alexander Staruschenko1, 4 1 Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA 2 Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA 3 Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA 4 Kidney Disease Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA Correspondence should be addressed to Alexander Staruschenko, [email protected] Received 6 January 2010; Revised 16 March 2010; Accepted 14 April 2010 Academic Editor: Tianxin Yang Copyright © 2010 Tengis S. Pavlov et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Peroxisome proliferator-activated receptors (PPARs) are members of a steroid hormone receptor superfamily that responds to changes in lipid and glucose homeostasis. Peroxisomal proliferator-activated receptor subtype γ (PPARγ)hasreceivedmuch attention as the target for antidiabetic drugs, as well as its role in responding to endogenous compounds such as prostaglandin J2. However, thiazolidinediones (TZDs), the synthetic agonists of the PPARγ are tightly associated with fluid retention and edema, as potentially serious side effects. The epithelial sodium channel (ENaC) represents the rate limiting step for sodium absorption in the renal collecting duct. Consequently, ENaC is a central effector impacting systemic blood volume and pressure. The role of PPARγ agonists on ENaC activity remains controversial.
    [Show full text]
  • Pharmaceuticals Compositions Comprising Sulphonylurea-Class Insulin Secretagogue and Polyethylene Glycol Castor Oil
    (19) & (11) EP 2 438 911 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.04.2012 Bulletin 2012/15 A61K 9/20 (2006.01) A61K 31/4439 (2006.01) A61K 31/64 (2006.01) A61K 9/16 (2006.01) (21) Application number: 10013440.2 (22) Date of filing: 08.10.2010 (84) Designated Contracting States: (72) Inventor: The designation of the inventor has not AL AT BE BG CH CY CZ DE DK EE ES FI FR GB yet been filed GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hodzar, Damjan et al Designated Extension States: Lek Pharmaceuticals d.d. BA ME Verovskova 57 1526 Ljubljana (SI) (71) Applicant: LEK Pharmaceuticals d.d. 1526 Ljubljana (SI) (54) Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil (57) The present invention relates to the field of a rea-class insulin secretagogue active pharmaceutical in- pharmaceutical technology. More specifically, the gredient and at the same time, when both formulated into present invention relates to a pharmaceutical composi- a pharmaceutical composition, ensures satisfying or ex- tion comprising sulphonylurea-class insulin secreta- ceeding other parameters like for example stability, hard- gogue and a surface active agent. Surface active agent ness, friability and handling of said pharmaceutical com- obtainable by reacting castor oil or hydrogenated castor position. oil with ethylene oxide, preferably hydrogenated castor oil, substantially improves dissolution of the sulphonylu- EP 2 438 911 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 438 911 A1 Description Field of the invention 5 [0001] The present invention relates to the field of a pharmaceutical technology.
    [Show full text]
  • Curriculum Vitae
    David C. Klonoff MD, FACP, FRCP (Edin), Fellow AIMBE Page 1 CURRICULUM VITAE DAVID CHARLES KLONOFF, M.D., FACP, FRCP (Edin), FELLOW AIMBE Medical Director, Diabetes Research Institute, Mills-Peninsula Medical Center 100 South San Mateo Drive, Room 5147, San Mateo, California 94401 Phone 650-696-4260 / Fax 650-696-4269 [email protected] SUMMARY David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. He is the Founding Editor- in-Chief of Journal of Diabetes Science and Technology. He has authored over 270 publications in PubMed journals including four of the first ten articles on diabetes device cybersecurity.
    [Show full text]
  • Possible Role of Rivoglitazone Thiazolidine Class of Drug As Dual
    Medical Hypotheses 131 (2019) 109305 Contents lists available at ScienceDirect Medical Hypotheses journal homepage: www.elsevier.com/locate/mehy Possible role of rivoglitazone thiazolidine class of drug as dual-target therapeutic agent for bacterial infections: An in silico study T ⁎ Vidyasrilekha Yele , Niladri Saha, Afzal Azam Md Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Ootacamund, JSS Academy of Higher Education & Research, Mysuru 643001, India ARTICLE INFO ABSTRACT Keywords: Infections due to resistant bacteria are the life-threatening and leading cause of mortality worldwide. The Rivoglitazone current therapy for bacterial infections includes treatment with various drugs and antibiotics. The misuse and ParE over usage of these antibiotics leads to bacterial resistance. There are several mechanisms by which bacteria MurE exhibit resistance to some antibiotics. These include drug inactivation or modification, elimination of antibiotics Docking through efflux pumps, drug target alteration, and modification of metabolic pathway. However, it is difficult to MM-GBSA treat infections caused by resistant bacteria by conventional existing therapy. In the present study binding af- Molecular dynamic simulations fi Anti-bacterial agent nities of some glitazones against ParE and MurE bacterial enzymes are investigated by in silico methods. As evident by extra-precision docking and binding free energy calculation (MM-GBSA) results, rivoglitazone ex- hibited higher binding affinity against both ParE and MurE enzymes compared to all other selected compounds. Further molecular dynamic (MD) simulations were performed to validate the stability of rivoglitazone/4MOT and rivoglitazone/4C13 complexes and to get insight into the binding mode of inhibitor. Thus, we hypothesize that structural modifications of the rivoglitazone scaffold can be useful for the development of an effective antibacterial agent.
    [Show full text]
  • Design, Synthesis, and Evaluation of Thiazolidinedione Derivatives Inhibiting Bcl-2/Bcl-Xl Or Ablating Androgen Receptor for the Treatment of Prostate Cancer
    DESIGN, SYNTHESIS, AND EVALUATION OF THIAZOLIDINEDIONE DERIVATIVES INHIBITING BCL-2/BCL-XL OR ABLATING ANDROGEN RECEPTOR FOR THE TREATMENT OF PROSTATE CANCER DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jian Yang, M.S. * * * * * The Ohio State University 2009 Dissertation Committee: Approved by Professor Ching-Shih Chen, Advisor Professor Pui-Kai (Tom) Li Adviser Professor Werner Tjarks Pharmacy Gradate Program Professor Dale Hoyt COPYRIGHT BY JIAN YANG 2009 ABSTRACT As of 2008, prostate cancer remains the number one cause of estimated new cancer cases in American men. Although early prostate cancer responds to androgen ablation, most tumors eventually recur as hormone-refractory prostate cancer (HRPC). Recent advances have identified many abnormal signaling pathways that contribute to the development of HRPC, mainly including dysregulation of androgen receptor (AR) function and the over- expression of the anti-apoptotic proteins, Bcl-2/Bcl-xL. It was found that thiazolidinediones (TZD), which include the anti-diabetic agents troglitazone, rosiglitazone, pioglitazone and ciglitazone, possess anti-tumor activity. It has been revealed that the anti-tumor activity of the TZDs could be attributed to PPARγ- independent mechanisms including Bcl-2/Bcl-xL inhibition and AR transcriptional repression. The objective of this dissertation is to further modify the TZD structures to enhance anti-prostate cancer activity by targeting the dysregulated Bcl-2/Bcl-xL and AR signaling pathways. Directed by method of molecular modeling, over 50 troglitazone derivatives have been designed and synthesized in two stages, yielding the optimal compound HepCNCF3, which showed two orders of magnitude improvement in Bcl-xL/Bcl-2 inhibition ii compared to troglitazone.
    [Show full text]